The Joint Corp (JYNT)vsMerck & Company Inc (MRK)
JYNT
The Joint Corp
$7.75
-4.32%
HEALTHCARE · Cap: $114.56M
MRK
Merck & Company Inc
$149.32
+0.40%
HEALTHCARE · Cap: $365.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 113596% more annual revenue ($66.57B vs $58.55M). JYNT leads profitability with a 6.5% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.76. JYNT earns a higher WallStSmart Score of 49/100 (D+).
JYNT
Hold49
out of 100
Grade: D+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JYNT.
Margin of Safety
-78.2%
Fair Value
$83.04
Current Price
$149.32
$66.28 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 653.0% YoY
Every $100 of equity generates 21 in profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.5% margin — thin
Operating margin of 3.3%
Expensive relative to growth rate
Trading at 8.8x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : JYNT
The strongest argument for JYNT centers on EPS Growth, Return on Equity, Debt/Equity. Revenue growth of 14.4% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : JYNT
The primary concerns for JYNT are Market Cap, Profit Margin, Operating Margin. A P/E of 57.9x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
JYNT carries more volatility with a beta of 1.06 — expect wider price swings.
JYNT is growing revenue faster at 14.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JYNT scores higher overall (49/100 vs 36/100) and 14.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
The Joint Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Joint Corp. The company is headquartered in Scottsdale, Arizona.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?